Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARO-ALK7 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Part 1 and Part 2 (optional cohort): ARO-ALK7 | EXPERIMENTAL | ARO-ALK7 in single (Day 1) or multiple (Days 1 and 85) ascending doses |
| Part 1 and Part 2 (optional cohort): Placebo | PLACEBO_COMPARATOR | Placebo in single (Day 1) or multiple (Days 1 and 85) matching doses |
| Part:2: ARO-ALK7 + Tirzepatide | EXPERIMENTAL | ARO-ALK7 at ascending doses on Days 1 and 85 plus weekly doses of tirzepatide initiated at Day 15 through Day 253 |
| Part 2: Placebo + Tirzepatide | PLACEBO_COMPARATOR | Placebo dose on Days 1 and 85 plus weekly doses of tirzepatide initiated at Day 15 through Day 253 |
| Name | Type | Description |
|---|---|---|
| ARO-ALK7 | DRUG | Subcutaneous (SC) injection |
| Placebo | DRUG | calculated volume to match active treatment by SC injection |
Inclusion Criteria: * Obesity, defined as body mass index (BMI) between 30-50 kilograms (kg)/square meter (m\^2), inclusive, with weight at Screening not to exceed 159 kg (350 pounds \[lbs\]) * At least one self-reported, unsuccessful attempt at weight loss with lifestyle modification * No abnormal...
Top 20 of 33 competitors